A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy

In conclusion, there is no difference between the effects of lisinopril versus losartan on EF improvement in DMD boys with CM. The drugs were safe. Thus, this study opens the opportunity to study muscle function in younger boys with DMD to see if the skeletal muscle improvement seen in the mdx mouse following treatment with an ARB might also be demonstrated in DMD boys. 17 Competing Interests The authors have declared that no competing interests exist. Correspondence Hugh D. Allen MD, Heart Center, Texas Children’s Hospital, 6621 Fannin St. Suite 19469, Houston, TX, 77030 E-mail: hdallen@texaschildrens.org Author Contributions Drs. Allen and Mendell conceived the study, wrote the grant oversaw data collection, and wrote the paper. Dr. Allen saw all Nationwide Children’s patients, re-read all echoes and coordinated the study. Dr. Flanigan reviewed the data, reviewed the paper and coordinated statistical testing Dr. Thrush reviewed all echoes, evaluated patients, reviewed the paper and helped with its development. Drs. Dvorchik and Yin did the statistical analysis and participated in writing the paper. Drs. Canter and Connolly were site evaluators at St. Louis Children’s Hospital, provided patients, performed and read echoes and reviewed the paper. Drs. Parrish and Mcdonald were site evaluators at UC Davis, provided patients, performed and read echoes and reviewed the paper. Drs. Braunlin and Day were site evaluators at the University of Minnesota, provided patients...
Source: PLOS Currents Muscular Dystrophy - Category: Neurology Authors: Source Type: research